Trial Profile

An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bempedoic acid (Primary)
Indications Hyperlipoproteinaemia type IIa
Focus Pharmacokinetics
Acronyms CLEAR Path 1
Sponsors Esperion Therapeutics

Most Recent Events

19 Jun 2026 According to an Esperion Therapeutics media release, data from this study were presented as moderated Science at a Glance sessions at the European Atherosclerosis Society (EAS) Congress 2026 taking place on May 24-27,2026, in Athens, Greece.
26 May 2026 Results presented in an Esperion Therapeutics Media Release.
13 May 2026 Results presented in an Esperion Therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com